Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

No Evidence of SARS-CoV-2 Infection in Urban Wildlife of Hokkaido, Japan.

Anastasiia Kovba | Naganori Nao | Michito Shimozuru | Mariko Sashika | Chihiro Takahata | Kei Sato | Keiya Uriu | Masami Yamanaka | Masanao Nakanishi | Genta Ito | Mebuki Ito | Miku Minamikawa | Kotaro Shimizu | Koichi Goka | Manabu Onuma | Keita Matsuno | Toshio Tsubota
Transboundary and emerging diseases | 2024

Various domestic and wildlife species have been found susceptible to and infected with SARS-CoV-2, the causative agent of COVID-19, around the globe, raising concerns about virus adaptation and transmission to new animal hosts. The virus circulation in the white-tailed deer population in North America has further called to action for virus surveillance in the wildlife. Here, we report on the first SARS-CoV-2 survey of wild animals in Japan, where frequent wildlife invasions of urban areas have occurred due to the limited predation, field abandonment, the increase of human acclimatization. Genetic testing using nasal swabs and serological screening have been conducted for sika deer, brown bears, raccoons, and raccoon dogs captured in Hokkaido prefecture from the end of the Delta variant wave to the spread of the Omicron variant, between March 2022 and February 2023. No viral RNA was detected in raccoons (0/184), sika deer (0/107), and brown bears (0/14) indicating that the virus was unlikely to spread within the population of these animal species. Among 171 raccoons, 20 raccoon dogs, 100 sika deer, and 13 brown bears, one raccoon, one brown bear, and two deer tested positive in the antibodies screening with multispecies SARS-CoV-2 N-protein ELISA. Still, ELISA-positive samples tested negative in three other serological tests, emphasizing the importance of confirming serological screening results. Our results suggested that SARS-CoV-2 was unlikely to spillback from humans to wildlife in Hokkaido during the study period, with the emergence of new variants, continuous surveillance is of utmost importance.

Pubmed ID: 40303042

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


BioVision (tool)

RRID:SCR_005057

An Antibody supplier

View all literature mentions

Promega (tool)

RRID:SCR_006724

An Antibody supplier

View all literature mentions

Thermo Fisher Scientific (tool)

RRID:SCR_008452

Commercial vendor and service provider of laboratory reagents and antibodies. Supplier of scientific instrumentation, reagents and consumables, and software services.

View all literature mentions

Sigma-Aldrich (tool)

RRID:SCR_008988

American chemical, life science and biotechnology company owned by Merck KGaA. Merger of Sigma Chemical Company and Aldrich Chemical Company. Provides organic and inorganic chemicals, building blocks, reagents, advanced materials and stable isotopes for chemical synthesis, medicinal chemistry and materials science, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, proteins, peptides, amino acids and their derivatives.

View all literature mentions

Abcam (tool)

RRID:SCR_012931

A commercial antibody supplier which supplies primary and secondary antibodies, biochemicals, proteins, peptides, lysates, immunoassays and other kits.

View all literature mentions